L-CsA, a Liposomal Formulation of Cyclosporine A, Demonstrates Therapeutic Potential for Bronchiolitis Obliterans Syndrome (BOS)

Abstract

blockage of the bronchioles, resulting in respiratory failure and death4,5 – Currently, there is no approved therapy for the prevention or treatment of BOS6 • Prior studies with inhaled propylene glycol-based cyclosporine demonstrated that acute rejection was not prevented but that there was significant BOS-free survival7 – Propylene glycol-based cyclosporine is poorly tolerated and poorly aerosolized (CYCLIST trial)8 • Liposomal Cyclosporine A for inhalation (L-CsA-i) is a true liposome of cyclosporine A designed for inhaled delivery to the lungs (administered via the high-performance PARI eFlow® Nebulizer System) (Fig 3) L-CsA-i, a Liposomal Formulation of Cyclosporine, Demonstrates Therapeutic Potential for Bronchiolitis Obliterans Syndrome (BOS)